State Street Corporation and its subsidiary SSGA Funds Management, Inc. filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership positions in Ultragenyx Pharmaceutical Inc. as of September 30, 2026.

Key Highlights

  • State Street Corporation aggregate stake: 7,538,078 shares, representing 7.6% of Ultragenyx Pharmaceutical common stock.
  • SSGA Funds Management stake: 5,318,630 shares, representing 5.4% of the class, reported separately as an investment adviser.
  • Shared voting power (State Street Corporation): 7,245,178 shares; sole voting power reported as 0.
  • Shared dispositive power (State Street Corporation): 7,538,078 shares; sole dispositive power reported as 0.
  • Event date: September 30, 2026, with the filing signed on November 9, 2026.
  • Subsidiaries listed: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd., all classified as investment advisers.

State Street and SSGA Funds Management Disclose Ultragenyx Holdings as of September 30, 2026

According to the Schedule 13G filing, State Street Corporation, a Massachusetts-incorporated holding company, reported aggregate beneficial ownership of 7,538,078 shares of Ultragenyx Pharmaceutical Inc. common stock (CUSIP 90400D108), equal to 7.6% of the class. The filing indicates that State Street Corporation holds no sole voting or sole dispositive power over these shares, with shared voting power covering 7,245,178 shares and shared dispositive power covering the full 7,538,078 shares.

SSGA Funds Management, Inc., a Massachusetts-incorporated investment adviser and subsidiary of State Street Corporation, filed separately within the same document. The subsidiary reported beneficial ownership of 5,318,630 shares, or 5.4% of the class, with shared voting power over 5,303,530 shares and shared dispositive power over 5,318,630 shares. Sole voting and sole dispositive power are each reported as 0 for SSGA Funds Management, Inc. as well.

The filing identifies five subsidiaries through which the parent holding company acquired the reported securities: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd., each classified as an investment adviser. The certifications state that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing was signed by Alok Maheshwary, Senior Vice President of State Street Corporation, and Brian Harris, Chief Compliance Officer of SSGA Funds Management, Inc., both on November 9, 2026. Ultragenyx Pharmaceutical Inc. is headquartered at 60 Leveroni Court, Novato, California 94949, according to the filing.

What Was Disclosed

State Street Corporation and SSGA Funds Management, Inc. disclosed beneficial ownership positions in Ultragenyx Pharmaceutical Inc. common stock as of September 30, 2026, with State Street Corporation reporting 7,538,078 shares (7.6%) and SSGA Funds Management reporting 5,318,630 shares (5.4%).